Trial Profile
Biomarkers as predictotors of response to bevacizumab based chemotherapy in patients with stage IV non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 26 Apr 2017 New trial record